Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 6:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 105 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage IB Pancreatic Cancer Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Interventions
BEZ235 + MEK162
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Paricalcitol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Cancer of Pancreas, Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Neoplasms
Interventions
M7824, Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced May 21, 2026, 6:19 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Stage I Adult Liver Cancer, Stage I Colorectal Cancer, Stage IA Gastric Cancer, Stage IA Pancreatic Cancer, Stage IB Gastric Cancer, Stage IB Pancreatic Cancer, Stage II Adult Liver Cancer, Stage IIA Colorectal Cancer, Stage IIA Gastric Cancer, Stage IIA Pancreatic Cancer, Stage IIB Colorectal Cancer, Stage IIB Gastric Cancer, Stage IIB Pancreatic Cancer, Stage IIC Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Adult Liver Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Gastric Cancer, Stage IIIB Adult Liver Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Gastric Cancer, Stage IIIC Adult Liver Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer, Stage IVA Colorectal Cancer, Stage IVA Liver Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Liver Cancer, Stage IVB Pancreatic Cancer
Interventions
Computer-Assisted Intervention, Vivofit watch, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis, pharmacological study, neoadjuvant therapy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
6
States / cities
Beverly Hills, California • Duarte, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2013 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Pancreatic Cancer
Interventions
Gemcitabine, Nab-paclitaxel, ALT-803
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
PRI-724
Drug
Lead sponsor
Prism Pharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced May 21, 2026, 6:19 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC), Borderline Resectable Pancreatic Cancer, Pancreatic Neoplasms
Interventions
Gemcitabine Delivered by Transarterial Microperfusion
Combination Product
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer, Periampullary Adenocarcinoma, Small Intestine Cancer
Interventions
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
ProAgio Dose Levels (DL) 1,2,3,4, Gemcitabine, nab paclitaxel
Drug
Lead sponsor
ProDa BioTech, LLC
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cancer
Interventions
therapeutic allogeneic lymphocytes
Biological
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 5, 2015 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Anti-SEMA4D Monoclonal Antibody VX15/2503, Ipilimumab, Nivolumab, Surgery
Biological · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced May 21, 2026, 6:19 PM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Rectal Adenocarcinoma, Stage III Pancreatic Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Oxaliplatin, pan FGFR Kinase Inhibitor BGJ398, Pharmacological Study
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LDE225+gemcitabine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced May 21, 2026, 6:19 PM EDT
Terminated Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
Interventions
MEK162, AMG 479
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
2
States / cities
Boston, Massachusetts • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Carcinoma, Recurrent Hepatocellular Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Gallbladder Cancer AJCC V7, Stage III Hepatocellular Carcinoma AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma, Unresectable Pancreatic Carcinoma
Interventions
Durvalumab, Guadecitabine
Biological · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8
Interventions
Durvalumab, Gemcitabine, Nab-paclitaxel, Oleclumab
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced May 21, 2026, 6:19 PM EDT
Withdrawn Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable, Pancreatic Ductal Adenocarcinoma, Pancreatic Metastasis
Interventions
Ascorbic Acid, Paclitaxel protein-bound, Cisplatin, Gemcitabine
Drug
Lead sponsor
Hitendra Patel
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced May 21, 2026, 6:19 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
PTM-101
Drug
Lead sponsor
PanTher Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Newport Beach, California • Detroit, Michigan • Lake Success, New York + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 6:19 PM EDT
Suspended Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Cancer, Adenocarcinoma of the Pancreas, Squamous Cell Carcinoma of Pancreas, Adenosquamous Carcinoma of the Pancreas
Interventions
ZIMBERELIMAB, DOMVANALIMAB, APX005M, FOLFIRI
Drug
Lead sponsor
James Cleary, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Neoplasms, Pancreatic Neoplasms
Interventions
LMB-100, Nab-Paclitaxel, Mesothelin Expression
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced May 21, 2026, 6:19 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Biliary Tract Carcinoma, Metastatic Colon Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma, Stage IV Colon Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Pemetrexed, PRMT5 Inhibitor BMS-986504
Procedure · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 6:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
PEGPH20, Oxaliplatin, Leucovorin, Irinotecan, 5-fluorouracil
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
154
States / cities
Anchorage, Alaska • Tucson, Arizona • Auburn, California + 112 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced May 21, 2026, 6:19 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Malignant Solid Neoplasm, Pathologic Stage II Gastric Cancer AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastric Cancer AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Stage I Pancreatic Cancer AJCC v8, Stage IA Pancreatic Cancer AJCC v8, Stage IB Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8, Stage IIB Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Malignant Digestive System Neoplasm, Small Intestinal Adenocarcinoma, Stage III Small Intestinal Adenocarcinoma AJCC v8, Stage IIIA Small Intestinal Adenocarcinoma AJCC v8
Interventions
Adenovirus 5/F35-Human Guanylyl Cyclase C-PADRE
Biological
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 21, 2026, 6:19 PM EDT